GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Profitability Rank
中文

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Profitability Rank : 7 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Profitability Rank?

Taro Pharmaceutical Industries has the Profitability Rank of 7.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Taro Pharmaceutical Industries's Operating Margin % for the quarter that ended in Dec. 2023 was 10.11%. As of today, Taro Pharmaceutical Industries's Piotroski F-Score is 9999.


Competitive Comparison of Taro Pharmaceutical Industries's Profitability Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries's Profitability Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Profitability Rank falls into.



Taro Pharmaceutical Industries Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Taro Pharmaceutical Industries has the Profitability Rank of 7.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Taro Pharmaceutical Industries's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=15.883 / 157.145
=10.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Taro Pharmaceutical Industries has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Taro Pharmaceutical Industries Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -36.5%.

4. Consistency of the profitability

5. Predictability Rank


Taro Pharmaceutical Industries Profitability Rank Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro to Announce First Quarter Results on July 29, 2020

By Business Wire Business Wire 07-22-2020

Taro Completes Acquisition of Alchemee

By Business Wire Business Wire 03-01-2022

Taro to Announce Third Quarter Results on January 27, 2021

By Business Wire Business Wire 01-21-2021

Taro to Announce Second Quarter Results on October 28, 2021

By Business Wire Business Wire 10-21-2021

Taro to Announce First Quarter Results on July 27, 2021

By Business Wire Business Wire 07-21-2021

Taro to Announce Full Year Results on May 19, 2021

By Business Wire Business Wire 05-12-2021

Taro to Release Third Quarter Results on January 24, 2023

By Business Wire Business Wire 01-19-2023

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

By Business Wire Business Wire 09-28-2020